Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II Study to Evaluate the Safety and Efficacy of Enfortumab Vedotin Plus Pembrolizumab in Combination With Quemliclustat in Unresectable Locally Advanced and Metastatic Urothelial Carcinoma

NCT07667335 is registered in ClinicalTrials.gov with Fred Hutchinson Cancer Center as lead sponsor.

NCT NCT07667335
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07667335 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II Study to Evaluate the Safety and Efficacy of Enfortumab Vedotin Plus Pembrolizumab in Combination With Quemliclustat in Unresectable Locally Advanced and Metastatic Urothelial Carcinoma
Lead sponsor
Fred Hutchinson Cancer Center
Phase
Phase 1/2
Overall status
Recruiting
Start date
October 15, 2026
Completion date
July 16, 2029
Enrollment
27 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced bladder urothelial carcinoma, locally advanced renal pelvis urothelial carcinoma, locally advanced ureter urothelial carcinoma, metastatic bladder giant cell urothelial carcinoma, metastatic renal pelvis urothelial carcinoma, metastatic ureter urothelial carcinoma, stage iiib bladder cancer ajcc v8, stage iv bladder cancer ajcc v8, stage iv renal pelvis cancer ajcc v8, stage iv ureter cancer ajcc v8, unresectable bladder urothelial carcinoma, unresectable renal pelvis urothelial carcinoma, unresectable ureter urothelial carcinoma